What is a general inhaler?
The general inhaler is a pocket device that drives anti -inflammatory drugs into tapered airways and which, because it is not tested, tends to be significantly cheaper than the counterparts of the name tags. Since January 1, 2009, generic inhalers have been removed from the US market due to their chlorofluorocarbon -damaging ozone (CFC). Patent drug laws prohibit the release of a generic inhaler without CFC on the US market until 2012 or later. While the elimination of CFC inhalers is a positive step for US environmental law, it is a problem for those who have respiratory conditions who have to buy often unusual brand inhalers.
As with all generic drugs, while the active ingredients contained in the general inhaler are the same as the names contained in the names, it is not patented. So it tends to sell at a cheaper price than inhalers of names. In the past, generic inhalers have provided an affordable possibility to those who have respiratoryínky and limited revenue. In accordance with the 2005 Act, inhalers containing CFCs from the US market were removed from 1 January 2009. Drug manufacturers have developed inhalers without CFC to replace their now affected products. Instead of CFC, these new inhalers use less damaging the hydrophluoralkane (HFA). Given the patent laws, however, generic pharmaceutical companies cannot introduce a general HFA inhaler until 2012 or later.
From an ecological point of view, the ban is a CFC inhaler for US environmental right by a positive step. In fact, the ban is only one part of the US effort to eliminate the use of substances that exhaust the ozone layer. This IS effort is made in accordance with the Montreal Protocol, a contract created in 1987 to protect the ozone layer by removing global dependence on destructive substances.
In spite ofHowever, these environmental benefits have been proven to be problematic for many who suffer from respiratory conditions. As long as the patent is expired to the branded names of HFA-MULTOVS, which is not expected to show up until 2012 or later-German drug companies to start producing general versions of the device. Since September 2010, therefore, inhaler users have no choice but to buy HFA inhalers for the name, which estimates that at the time of their removal from the market is at least $ 20 (USD) more than the selling price of the CFC generic devices.